Associated Papers
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs.
Wang P et al.
Genome Biology, 2025
40696461 (PubMed )
Supplement: 13059_2025_3667_MOESM1_ESM.xlsx › Overlap_between_lines
The complexity of tobacco smoke-induced mutagenesis in head and neck cancer.
Torrens L et al.
Nature Genetics, 2025
40164736 (PubMed )
Supplement: 41588_2025_2134_MOESM4_ESM.xlsx › Supplementary_Table_15
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
Yao J et al.
Frontiers in Immunology, 2025
40519936 (PubMed )
Supplement: Table1.xlsx › SNV
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.
Erices JI et al.
Frontiers in Oncology, 2025
Implementing Massive Parallel Sequencing into Biliary Samples Obtained through Endoscopic Retrograde Cholangiopancreatography for Diagnosing Malignant Bile Duct Strictures.
Park W et al.
International Journal of Molecular Sciences, 2024
miR-876-3p is a tumor suppressor on 9p21 that is inactivated in melanoma and targets ERK.
Bezrookove V et al.
Journal of Translational Medicine, 2024
Genomic progression for local invasion of cutaneous squamous cell carcinoma from the superficial to the deep portion.
Hwang HW et al.
International Journal of Cancer, 2024
Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.
Song M et al.
Bmc Cancer, 2024
38825709 (PubMed )
Supplement: 12885_2024_12407_MOESM2_ESM.xlsx › Table_S3
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
38611025 (PubMed )
Supplement: cancers-16-01347-s001.zip › cancers-2874995-supplementary.xlsx › TableS1
Expanding Broad Molecular Reflex Testing in Non-Small Cell Lung Cancer to Squamous Histology.
Zacharias M et al.
Cancers, 2024
38473263 (PubMed )
Supplement: cancers-16-00903-s001.zip › TableS2.xlsx › Tabelle
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A et al.
Diagnostics (basel, Switzerland), 2023
37761329 (PubMed )
Supplement: diagnostics-13-02962-s001.zip › supplementary__Table_S2.xlsx › Table_S2_Samples_analyzed
Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer.
Levink IJM et al.
International Journal of Molecular Sciences, 2023
Targeted deep sequencing reveals genomic alterations of actinic keratosis/cutaneous squamous cell carcinoma in situ and cutaneous squamous cell carcinoma.
Kim YS et al.
Experimental Dermatology, 2023
Clear cell variant of atypical fibroxanthoma and pleomorphic dermal sarcoma: Molecular characterization and review of the literature.
Coelho-Lima J et al.
Journal of Cutaneous Pathology, 2022
NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G et al.
Cell Reports, 2022
36351408 (PubMed )
Supplement: NIHMS1848910-supplement-2.xlsx › NF1-TP53-pi16INK4A-Smad4
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C et al.
Nature Communications, 2022
35882862 (PubMed )
Supplement: 41467_2022_31963_MOESM13_ESM.xlsx › Sheet1
Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.
Bastidas Torres AN et al.
Haematologica, 2022
33792220 (PubMed )
Supplement: 2020_274506_TORRES_SUPPL.pdf
RNA-SSNV: A Reliable Somatic Single Nucleotide Variant Identification Framework for Bulk RNA-Seq Data.
Long Q et al.
Frontiers in Genetics, 2022
35846154 (PubMed )
Supplement: Table3.XLSX › LUSC_RNA_DNA_overlap
Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.
Thind AS et al.
Frontiers in Oncology, 2022
35982973 (PubMed )
Supplement: Table_4.xls › Variant_details_of_coding_drive
The LOVD3 platform: efficient genome-wide sharing of genetic variants.
Fokkema IFAC et al.
European Journal of Human Genetics : Ejhg, 2021
34521998 (PubMed )
Supplement: 41431_2021_959_MOESM4_ESM.pdf
TERT gene rearrangement in chordomas and comparison to other TERT-rearranged solid tumors.
Yoon JY et al.
Cancer Genetics, 2021
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.
Nakamura IT et al.
Npj Precision Oncology, 2021
34272467 (PubMed )
Supplement: 41698_2021_204_MOESM6_ESM.xlsx › Supplementary_Data_4
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer.
Zhang J et al.
Frontiers in Oncology, 2021
33996580 (PubMed )
Supplement: Table_1.xlsx › Sheet1
Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population.
Ju Y et al.
Frontiers in Genetics, 2021
34194478 (PubMed )
Supplement: Data_Sheet_1.xlsx › Table_S6
Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas.
Cui Y et al.
Plos One, 2021
34478472 (PubMed )
Supplement: pone.0256979.s002.xlsx › TCGA-HNSC
CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.
Lin JC et al.
Journal of Clinical Medicine, 2020
33322698 (PubMed )
Supplement: jcm-09-04019-s001.zip › jcm-1006906supple › Table-S1-TCGA-data.xlsx › _f__LUSC
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
33173047 (PubMed )
Supplement: 41467_2020_19342_MOESM7_ESM.xlsx › PGI_fudan_NC_clnical.oc
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML et al.
Cells, 2020
31936151 (PubMed )
Supplement: cells-09-00142-s001.pdf
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_9_Accuracy_Short_Variant_Line_Data.xlsx › sheet_1
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
31745186 (PubMed )
Supplement: 41598_2019_52000_MOESM2_ESM.xlsx › Sheet1
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I et al.
Cell Death & Disease, 2019
31506424 (PubMed )
Supplement: 41419_2019_1875_MOESM2_ESM.pdf
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
30736836 (PubMed )
Supplement: 13058_2019_1102_MOESM2_ESM.xlsx › Sheet1
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Nayar U et al.
Nature Genetics, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
30064409 (PubMed )
Supplement: 12894_2018_380_MOESM1_ESM.xlsx › Supplementary_Table_1
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA et al.
Nature Medicine, 2018
Toward an integrated map of genetic interactions in cancer cells.
Rauscher B et al.
Molecular Systems Biology, 2018
29467179 (PubMed )
Supplement: MSB-14-e7656-s003.xlsx › Dataset_EV2
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
29161613 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis.
Koh KX et al.
Oncotarget, 2017
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD et al.
Genome Medicine, 2017
29082853 (PubMed )
Supplement: 13073_2017_478_MOESM1_ESM.xlsx › Table_S2
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.
Arildsen NS et al.
Frontiers in Oncology, 2017
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L et al.
Oncotarget, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A et al.
Genome Medicine, 2016
27460824 (PubMed )
Supplement: 13073_2016_333_MOESM4_ESM.xlsx › all_matched_muts.maf
Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.
Fadlullah MZ et al.
Oncotarget, 2016
27050151 (PubMed )
Supplement: oncotarget-07-27802-s001.pdf
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM et al.
Oncotarget, 2016
26992220 (PubMed )
Supplement: oncotarget-07-24172-s002.xlsx › Sheet1
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
26527317 (PubMed )
Supplement: oncotarget-06-43731-s002.xlsx › Table_S1
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
26009992 (PubMed )
Supplement: oncotarget-06-24499-s002.xlsx › Supplementary_Table_1
1–50 of 63 papers
Select a paper to view details